Thrombin generation and procoagulant phospholipids in patients with essential thrombocythemia and reactive thrombocytosis

American Journal of Hematology

Volumn 88, Issue 12, 2013, Pages 1007-1011

  Mignon, I ^a   Grand, F ^a   Boyer, F ^a   Hunault Berger, M ^a   Hamel, J F ^a   Macchi, L ^a,b  

^a ANGERS UNIVERSITY HOSPITAL   (France)

^b UNIVERSITÉ D'ANGERS   (France)

Author keywords

[No Author keywords available]

Indexed keywords

JANUS KINASE 2; PHOSPHOLIPID; PROCOAGULANT;

ADULT; AGED; ARTERY THROMBOSIS; ARTICLE; BLOOD CLOTTING PARAMETERS; BLOOD CLOTTING TIME; CALIBRATED AUTOMATED THROMBOGRAPHY; CHRONOMETRIC STANDARDIZED METHOD; CONTROLLED STUDY; ENDOGENOUS THROMBIN POTENTIAL; FEMALE; GENE MUTATION; HEMATOLOGICAL PROCEDURE; HUMAN; LAG; MAJOR CLINICAL STUDY; MALE; MEDICAL HISTORY; PREDICTIVE VALUE; PRIORITY JOURNAL; REACTIVE THROMBOCYTOSIS; THROMBIN TIME; THROMBOCYTHEMIA; THROMBOCYTOSIS; VEIN THROMBOSIS; VELOCITY INDEX;

ADULT; AGED; AGED, 80 AND OVER; AREA UNDER CURVE; BLOOD COAGULATION TESTS; COLORIMETRY; FEMALE; FLUOROMETRY; HUMANS; JANUS KINASE 2; MALE; MIDDLE AGED; PHOSPHOLIPIDS; POINT MUTATION; PREDICTIVE VALUE OF TESTS; ROC CURVE; THROMBIN; THROMBOCYTHEMIA, ESSENTIAL; THROMBOCYTOSIS; THROMBOPHILIA;

EID: 84888074045     PISSN: 03618609     EISSN: 10968652     Source Type: Journal    
DOI: 10.1002/ajh.23553     Document Type: Article

References (27)

1. Bleeker JS, Hogan WJ. Thrombocytosis: Diagnostic evaluation, thrombotic risk stratification, and risk-based management strategies. Thrombosis 2011;2011:536062. Epub.2011 Jun 8.
2. Skoda RC. Thrombocytosis. Hematology Am Soc Hematol Educ Program 2009:159-167.
3. James C, Ugo V, Le Couedic JP, et al. A unique clonal JAK2 mutation leading to constitutive signalling causes polycythaemia vera. Nature 2005;434:1144-1148.
4. Baxter EJ, Scott LM, Campbell PJ, et al. Acquired mutation of the tyrosine kinase JAK2 in human myeloproliferative disorders. Lancet 2005;365:1054-1061.
5. Kralovics R, Passamonti F, Buser AS, et al. A gain-of-function mutation of JAK2 in myeloproliferative disorders. N Engl J Med 2005;352:1779-1790.
6. Landolfi R, Cipriani MC, Novarese L. Thrombosis and bleeding in polycythemia vera and essential thrombocythemia: Pathogenetic mechanisms and prevention. Best Pract Res Clin Haematol 2006;19:617-633.
7. Elliott MA, Tefferi A. Thrombosis and haemorrhage in polycythaemia vera and essential thrombocythaemia. Br J Haematol 2005;128:275-290.
8. Carobbio A, Finazzi G, Guerini V, et al. Leukocytosis is a risk factor for thrombosis in essential thrombocythemia: Interaction with treatment, standard risk factors, and Jak2 mutation status. Blood 2007;109:2310-2313.
9. Wehmeier A, Südhoff T, Meierkord F. Relation of platelet abnormalities to thrombosis and hemorrhage in chronic myeloproliferative disorders. Semin Thromb Hemost 1997;23:391-402.
10. Falanga A, Marchetti M, Evangelista V, et al. Polymorphonuclear leukocyte activation and hemostasis in patients with essential thrombocythemia and polycythemia vera. Blood 2000;96:4261-4266.
11. Robertson B, Urquhart C, Ford I, et al. Platelet and coagulation activation markers in myeloproliferative diseases: Relationships with JAK2 V617F status, clonality, and antiphospholipid antibodies. J Thromb Haemost 2007;5:1679-1685.
12. Arellano-Rodrigo E, Alvarez-Larrán A, Reverter JC, et al. Increased platelet and leukocyte activation as contributing mechanisms for thrombosis in essential thrombocythemia and correlation with the JAK2 mutational status. Haematologica 2006;91:169-175.
13. Falanga A, Marchetti M, Vignoli A, et al. Leukocyte-platelet interaction in patients with essential thrombocythemia and polycythemia vera. Exp Hematol 2005;33:523-530.
14. Villmow T, Kemkes-Matthes B, Matzdorff AC. Markers of platelet activation and platelet-leukocyte interaction in patients with myeloproliferative syndromes. Thromb Res 2002;108:139-145.
15. Trappenburg MC, van Schilfgaarde M, Marchetti M, et al. Elevated procoagulant microparticles expressing endothelial and platelet markers in essential thrombocythemia. Haematologica 2009;94:911-918.
16. Duchemin J, Ugo V, Ianotto J-C, et al. Increased circulating procoagulant activity and thrombin generation in patients with myeloproliferative neoplasms. Thromb Res 2010;126: 238-242.
17. Griesshammer M, Bangerter M, Sauer T, et al. Aetiology and clinical significance of thrombocytosis: Analysis of 732 patients with an elevated platelet count. J Intern Med 1999;245:295-300.
18. Moles-Moreau MP, Ternisien C, Tanguy-Schmidt A, et al. Flow cytometry-evaluated platelet CD36 expression, reticulated platelets and platelet microparticles in essential thrombocythaemia and secondary thrombocytosis. Thromb Res 2010;126:e394-396.
19. Tefferi A, Thiele J, Orazi A, et al. Proposals and rationale for revision of the World Health Organization diagnostic criteria for polycythemia vera, essential thrombocythemia, and primary myelotibrosis: Recommendations from an ad hoc international expert panel. Blood 2007;110:1092-1097.
20. Marchetti M, Castoldi E, Spronk HM, et al. Thrombin generation and activated protein C resistance in patients with essential thrombocythemia and polycythemia vera. Blood 2008;112:4061-4068.
21. Duchemin J, Pan-Petesch B, Arnaud B, et al. Influence of coagulation factors and tissue factor concentration on the thrombin generation test in plasma. Thromb Haemost 2008;99:767-773.
22. Van Cott EM, Smith EY, Galanakis DK. Elevated fibrinogen in an acute phase reaction prolongs the reptilase time but typically not the thrombin time. Am J Clin Pathol 2002;118:263-268.
23. Gerotziafas GT, Van Dreden P, Chaari M, et al. The acceleration of the propagation phase of thrombin generation in patients with steady-state sickle cell disease is associated with circulating erythrocyte-derived microparticles. Thromb Haemost 2012; 107: 1044-1052.
24. Strasser EF, Happ S, Weiss DR, et al. Microparticle detection in platelet products by three different methods. Transfusion 2012;53:156-166.
25. Lacroix R, Judicone C, Poncelet P, et al. Impact of pre-analytical parameters on the measurement of circulating microparticles: towards standardization of protocol. J Thromb Haemost 2012;10:437-446.
26. Cervantes F. Management of essential thrombocythemia. Hematology Am Soc Hematol Educ Program 2011;2011:215-221.
27. Panova-Noeva M, Marchetti M, Spronk HM, et al. Platelet-induced thrombin generation by the calibrated automated thrombogram assay is increased in patients with essential thrombocythemia and polycythemia vera. Am J Hematol 2011;86:337-342.